TNF antagonists withdrawal is not advised in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis of randomized controlled trials
Discontinuation of TNF antagonists in IBD patients in remission substantially increases the risk and accelerates the timing of relapse, though it lowers infection risk. Careful patient selection and close monitoring are essential if withdrawal is considered.
Authors
- Adnan Bhat
- Faryal Altaf
- Nadia Ahmed
- Huzaifa Ahmad Cheema (ORCID: https://orcid.org/0000-0001-6783-7137)
- Muhammad Abu Zar
- Essam Rashad
- Iqra Qazi
- Asma’a Munasar Ali Alsubari
- Prasun K. Jalal (ORCID: https://orcid.org/0000-0001-5353-2324)
- Amrutha Amrutha
- Dhanushan Gnanendran (ORCID: https://orcid.org/0000-0001-8534-6622)
- Taimour Rashid Choudhry
- Ahmed Adekunle Owolabi
- Aqsa Khan (ORCID: https://orcid.org/0000-0001-8501-7554)
- Mariam Amro Alsayed
Institutions
- Ain Shams University (EG)
- Mount Sinai Health System (US)
- King Edward Medical University (PK)
- Sana'a University (YE)
- Baylor College of Medicine (US)
- Saint Thomas Midtown Hospital (US)
- University of Florida (US)
- University of Jeddah (SA)
- Stockport NHS Foundation Trust (GB)
- Parkview Health (US)
- Baptist Hospital (US)
- Gastroenterology Medical Center and Hospital (IN)
- University Hospitals Plymouth NHS Trust (GB)
- Kettering General Hospital NHS Trust (GB)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- International Journal of Colorectal Disease
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1007/s00384-025-05047-w
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00